The global transcatheter pulmonary valve market size was valued at USD 31.01 million in 2015 and is projected to grow at a CAGR of 6.0% during the forecast period. The market is mainly driven by the increasing prevalence of various cardiovascular diseases such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases. The growing population with heart valve disorders and surging demand for pulmonary valve replacement are a few of the crucial factors that are expected to increase the need for transcatheter valves over the forecast period.
The technological advancement in valve replacement procedures is also amongst the few key factors that are expected to drive the industry. The growing number of product launches related to transcatheter heart valve technologies is one of the primary reasons that indicates its surging demand and adoption rate amongst the patient population.
U.S. transcatheter pulmonary valve market, by application, 2014 - 2025 (USD Million)
In 2015, the tetralogy of Fallot held the majority of the revenue share owing to the presence of a huge product base for this application and growing incidence of tetralogy of Fallot amongst both the geriatric and adult population. Moreover, other than this application, pulmonary stenosis and others are also amongst the spearheaded segments.
Since the technology is quite a niche, and there are only three approved devices available in the U.S., Canada, and some parts of Europe, there is no mature segment of this market. Many applications are still under the uncharted territory, which includes cardiac anomaly, atresia, and regurgitation. The aforementioned applications are expected to boost the transcatheter pulmonary valve market over the forecast period.
In 2016, the balloon-expanded transcatheter valve segment was leading the revenue share, accounting for the largest market share of approximately 65.6% in 2015. The segment held the majority of the shares due to the growing consumer adoption rate and the increasing development of new products.
Moreover, the balloon-expanded transcatheter valve is also the fastest-growing segment at a lucrative CAGR. The growing interest amongst the manufacturers in balloon-expanded technology and rising awareness regarding the accuracy and precision of the treatment result are some of the factors that are expected to support the growth over the next eight years.
Global transcatheter pulmonary valve market by technology, 2015 (%)
In 2015, the adult transcatheter pulmonary valve held a majority of market share owing to the presence of huge demand for medical devices amongst the adult population and increasing prevalence of disorders such as cardiac abnormalities, pulmonary stenosis, regurgitation, and tetralogy of Fallot.
However, the pediatric transcatheter pulmonary segment is expected to be the fastest-growing segment over the forecast period owing to the technological advancement in cardiac devices. The increasing number of pediatric population affected with pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders is one of the crucial factors that is expected to drive the market over the forecast period.
In 2015, tissue-engineered transcatheter pulmonary valve held the majority of the share owing to the present product base and huge demand for tissue-engineered heart valve to avoid several limitations of using synthetic heart valve.
Moreover, the tissue-engineering segment is anticipated to grow at a faster pace as compared to synthetic transcatheter pulmonary. The presence of a huge product base of bioprosthetics & tissue valves and growing investment by the private & the public players for the development of advanced tissue-engineered heart valve to avoid the complications related to progressive degeneration are some of the factors that are anticipated to boost the industry over the coming few years. For instance, XELTIS announced that it had developed the first bioabsorbable heart valve, which received positive results in the second clinical trial.
North America was the largest regional market with a revenue of approximately USD 24.99 million in 2015. However, Asia Pacific is expected to grow with a maximum CAGR of 29.2% over the forecast period of 2019 to 2025. As of 2015, there was no commercialized product available in various regions such as Asia Pacific, Latin America, and MEA. And also the ongoing clinical trials with the existing product base in the Asia Pacific region are expected to complete its study by 2017-18. Thus, in 2019 onwards it is expected to have a product launch in various regions such as Asia Pacific, Latin America, and MEA.
Emerging economies such as India and China account for the majority of the medical device export across the globe. The growing demand for innovative heart valves, increasing geriatric population, rising healthcare expenditure, and rapidly developing healthcare sector are some of the factors that are expected to drive the market.
Some of the key players in this industry include Boston Scientific Corporation, Braile Biomédica, Direct Flow Medical, Edwards Lifesciences Corporation, JenaValve Technology, Inc., St. Jude Medical, SYMETIS, Colibri Heart Valve, LLC, VENUS MEDTECH, and XELTIS.
The transcatheter pulmonary valve industry is oligopolistic and is dominated by Edwards Lifesciences Corporation, Medtronic, and CryoLife. These companies are actively scouting for potential start-ups and are collaborating with different research centers for new product development.
In February 2023, Medtronic relaunched its HarmonyTM Transcatheter Pulmonary Valve (TPV) replacement system for congenital heart disease
The base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Billion & CAGR from 2016 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, UK, Germany, Spain, Italy, Russia, France, Japan, China, Hong-Kong, Taiwan, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global transcatheter pulmonary valve market based on application, technology, end-use, raw materials, and region:
Application Outlook (Revenue, USD Million; 2014 - 2025)
Tetralogy of Fallot
Transcatheter Valve Technology Outlook (Revenue, USD Million; 2014 - 2025)
End-Use Outlook (Revenue, USD Million; 2014 - 2025)
Transcatheter Valve Raw Material Outlook (Revenue, USD Million; 2014 - 2025)
Regional Outlook (Revenue, USD Million; 2014 - 2025)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.